Dementia research turns to brain circuits — and to timing stimulation to their rhythms

Tau predicts how connectivity changes

A preprint on Alzheimer's disease reports that baseline tau burden in high-NFT regions of the medial temporal lobe predicts subsequent functional connectivity alterations. Tau is a protein that accumulates in the brains of people with Alzheimer's, and the finding links the amount present at the start to how brain networks change afterward. m:…9003

Serial mediation analysis supports a pathway linking tau burden to cognitive impairment through altered high-NFT medial temporal lobe connectivity in the precuneus and occipital regions. In other words, the analysis is consistent with a chain running from tau, through changed connectivity in specific regions, to worse cognition — a chain with a place to intervene, rather than a bare correlation. m:…9003

The same preprint reports an intervention result: HF-rTMS intervention in MCI patients is associated with cognitive improvement mediated by enhanced synaptic plasticity and precuneus-high-NFT medial temporal lobe connectivity. MCI is mild cognitive impairment, an early stage at which intervention still has something to protect. m:…9003

An EEG index that tracks the type of dementia

A preprint on clinical EEG reports that non-negative tensor decomposition of clinical EEG isolates four factors — posterior alpha, Rolandic beta, frontotemporal delta-theta, and posterior theta-slow alpha — that vary significantly across FDG-PET-defined neurodegenerative phenotypes. The factors are patterns in brain rhythms, and they differ by dementia type, which means a clinical EEG carries information about which disease is present. m:…3784

Posterior theta-slow alpha rhythms show phenotype-specific association, with eta-squared values from 0.082 to 0.147, after adjusting for overall slowing, effectively dissociating Alzheimer disease from frontotemporal syndromes. A subject-level EEG slowing index correlates with FDG-PET patterns associated with dementia with Lewy bodies, with r of 0.51 and P below 0.001. m:…3784

The numbers matter because they separate different jobs: overall slowing tracks how far the disease has progressed, while specific rhythms identify which disease is doing the damage. A test that does all of that from a clinical EEG would be cheap, widely available, and usable where brain scans are not. m:…3784

Stimulation timed to the brain's own rhythm

A preprint on brain stimulation reports that phase-specific stimulation of prefrontal beta oscillations modulates distinct cognitive processes. Peak-targeted rTMS of endogenous beta oscillations over the left DLPFC improves response inhibition, while trough-targeted rTMS of the same oscillations over the same region improves working memory. The same stimulation, aimed at a different phase of the brain's own rhythm, improves a different mental function. m:…9707

Phase-specific rTMS induces distinct DLPFC network expansions: peak stimulation enhances posterior centro-parietal connectivity, while trough stimulation expands anterior prefrontal networks. The effect is not just local to the stimulated spot; the network that expands depends on the phase targeted, which is the kind of specificity a therapy would need. m:…9707

Timing, in this work, is doing the work that dose used to do. Rather than stimulating harder, the researchers stimulated at the right moment in the rhythm, and the brain's own oscillation decided which function improved and which network expanded. m:…9707

Why it matters

Taken together, the preprints describe a shift in how dementia is studied and treated. Tau burden predicts connectivity change, and connectivity change sits on the path to cognitive impairment; EEG rhythms separate dementia types and track severity; and stimulation timed to a brain rhythm can improve a specific cognitive function and expand a specific network. m:…9003 m:…3784 m:…9707

The through-line is circuits: what changes in dementia is not just the amount of a protein but the behavior of the networks it disrupts, and the interventions that show promise act on those networks directly. That points drug and device development at a different target than before — not only clearing what accumulates, but restoring how the networks behave. m:…9003 m:…9707